Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. by Oshima Hiroko et al.
Induction of prostaglandin E2 pathway promotes
gastric hamartoma development with suppression
of bone morphogenetic protein signaling.
著者 Oshima Hiroko, Itadani Hiraku, Kotani










Induction of prostaglandin E2 pathway promotes gastric hamartoma 
development with suppression of bone morphogenetic protein 
signaling 
 
Hiroko Oshima1, Hiraku Itadani2, Hidehito Kotani2, Makoto Mark Taketo3, and 
Masanobu Oshima1
 
1Division of Genetics, Cancer Research Institute, Kanazawa University, Japan; 
2Oncology Department, Banyu Tsukuba Research Institute, Japan; 3Department of 




Corresponding author: Masanobu Oshima, Division of Genetics, Cancer 
Research Institute, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-0934, 




Running Title: Gastric hamartoma by BMP suppression and PGE2 induction 
 
Key words: gastric hamartoma, BMP, PGE2, COX-2, juvenile polyposis 
1 
Abstract 
Mutations in bone morphogenetic protein (BMP) receptor 1A (BMPR1A) are 
responsible for a subset of cases of juvenile polyposis (JP) syndrome that develops 
hamartomatous tumors in the gastrointestinal tract.  Mouse genetic studies have 
demonstrated that suppression of BMP signaling in the intestines causes JP-type 
hamartoma development.  Here, we generated K19-Nog transgenic mice expressing 
noggin, a BMP antagonist, in gastric epithelium.  However, inhibition of BMP 
signaling did not cause gastric phenotypes.  We thus crossed K19-Nog with 
K19-C2mE mice that expressed Ptgs2 and Ptges in the stomach to generate 
compound transgenic mice.  Expression of Ptgs2 and Ptges results in prostaglandin 
E2 (PGE2) biosynthesis, and both enzymes are induced in most human 
gastrointestinal tumors.  Importantly, K19-Nog/C2mE compound mice developed 
gastric hamartomas that were morphologically similar to those found in JP with 
mucin-containing dilated cysts and inflammatory infiltration.  Notably, treatment of 
K19-Nog/C2mE mice with a COX-2 inhibitor, celecoxib, significantly reduced tumor 
size with suppression of angiogenesis, suggesting that induction of the PGE2 
pathway together with inhibition of BMP signaling is required for gastric hamartoma 
development.  Moreover, microarray analyses revealed that canonical Wnt signaling 
target genes were not induced in K19-Nog/C2mE hamartomas, indicating that BMP 
inhibition and PGE2 induction lead to gastric hamartoma development independent 
of the Wnt/β-catenin pathway.  These results, taken together, suggest that the PGE2 
pathway is an effective preventive target against BMP-suppressed gastric 
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hamartomas, as well as for Wnt/β-catenin-activated adenocarcinomas. 
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Introduction 
Juvenile polyposis (JP) is a hereditary gastrointestinal hamartomatous 
polyposis syndrome (1).  Germline mutations in bone morphogenetic protein (BMP) 
receptor type IA gene (BMPR1A) have been found in a subpopulation of JP patients 
(2).  BMP ligands bind to a complex of the BMP receptor type II and type I, which 
leads to phosphorylation of Smad1,5,8, allowing them to form a complex with Smad4 
(3, 4).  These Smad complexes translocate to nuclei and function as transcription 
enhancers.  BMP signaling inhibits epithelial cell proliferation and promotes 
differentiation (5, 6), and suppression of BMP signaling in mice results in intestinal 
hamartomatous polyp development through activation of the PI3K-Akt pathway (6, 
7).  Moreover, intestinal epithelial cell-specific deletion of Bmpr1a results in 
elongated villi and crypt fission (8).  These results indicate that BMP signaling 
promotes intestinal epithelial differentiation, and thus suppression of the BMP 
pathway causes tumorigenesis.  Although the main affected site of tumors in JP 
patients is the colon, gastric polyps have been found in 14% of JP patients, and 
cancer risk in JP patients increases both in the colon and stomach (9, 10).  Recently, 
it was reported that disruption of Bmpr1a in mouse stomach results in development 
of tumorous lesions in squamocolumnar and gastrointestinal transition zones, 
suggesting that suppression of BMP signaling triggers tumor development also in 
the stomach (11). 
On the other hand, we found that expression of cyclooxigenase-2 (COX-2) and 
microsomal prostaglandin E synthase-1 (mPGES-1) is induced simultaneously in 
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gastrointestinal tumor tissues (12).  COX-2 and mPGES-1 are functionally coupled 
for biosynthesis of prostaglandin E2 (PGE2) (13) that plays a critical role in 
tumorigenesis in the gastrointestinal tract (14-17).  However, the role of the PGE2 
pathway in hamartomatous tumors is not understood.  We constructed transgenic 
mice expressing Nog encoding noggin in the gastric mucosa and crossed them with 
another transgenic mice expressing both Ptgs2 and Ptges encoding COX-2 and 
mPGES-1, respectively, (16).  We show that inhibition of BMP signaling is not 
sufficient for gastric tumorigenesis, but that BMP suppression together with PGE2 
induction causes development of JP-type gastric hamartoma.   
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Materials and Methods 
Mouse models.  K19-C2mE mice expressing Ptgs2 and Ptges; K19-Wnt1 mice 
expressing Wnt1; and K19-Wnt1/C2mE mice expressing Wnt1, Ptgs2, and Ptges, 
were described previously (16, 17).  pK19-Nog was constructed using keratin 19 
gene promoter, mouse Nog cDNA, and SV40 p(A) cassette (Fig. 1A).  The 
expression vector was microinjected into the fertilized eggs of F1 (C3H and 
C57BL/6) mice (CLEA, Japan) to generate K19-Nog mice.  Primer sequences used 
for genotyping: (F-5’-GTACGCGTGGAATGACCTAGG-3’, 
F-5’-GCAAAGGGTCGCTACAGACGT-3’).  Transgenic vector constructs are shown 
in Figure 1A.  K19-Nog and K19-C2mE mice were crossed to generate 
K19-Nog/C2mE mice.  Gastric phenotypes of these mice were examined at 30 
weeks of age.  For inhibition of COX-2, mice were administered p.o. with celecoxib 
(Pfizer) at 100 mg/kg/day for 3 weeks.  All animal experiments were carried out 
according to the protocol approved by Ethics Committees on Animal 
Experimentation of Kanazawa University. 
Real-time RT-PCR.  Total RNA was reverse-transcribed and PCR-amplified.  
Primer sets used in real-time RT-PCR for detection of Nog, Ptgs2, Ptger1, Ptger2, 
Ptger3 and Ptger4 were purchased (TakaraBio, Japan).   
Histology.  Tissues were fixed in 4% paraformaldehyde, paraffin-embedded, 
and sectioned at 4-μm thickness.  The following antibodies were used for 
immunostaining: anti-COX-2 (Cayman Chemical), anti-F4/80 (Serotec, Oxford, UK), 
anti-α-smooth muscle actin (α-SMA) (Sigma), anti-Ki-67, anti-von Willebrand factor 
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(DakoCytomation), and anti-phosphorylated Smad1,5,8 (Chemicon).  Staining signal 
was visualized using the Vectorstain Elite Kit (Vector Laboratories). 
X-ray CT.  K19-Nog/C2mE mice were subjected to X-ray CT using LaTheta 
LCT-100 (Aloka, Japan).  CT analyses were performed 1 week before celecoxib 
treatment and at 0, 1, 2 and 3 weeks after treatment.  Tumor size on CT images was 
measured using NIH Image software (NIH). 
Immunoblotting.  Tissue samples were homogenized in lysis buffer.  Protein 
samples were separated in a SDS-polyacrylamide gel.  Antibody for the active 
β-catenin (Upstate) was used.  The ECL detection system (Amersham) was used to 
detect specific signals. 
Microarray analyses. Total RNA were prepared from mouse stomach at 30 
weeks of age.  Expression profiles of the Wnt target genes 
(http://www.stanford.edu/~rnusse/wntwindow.html), cytokines, and chemokines 
were examined with the Affymetrix GeneChip system and Mouse Genome 430 2.0 
Arrays (Affymetrix).   
Statistical analyses.  Statistical analyses were carried out using Student’s 
t-test. 
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Results and Discussion 
Generation of K19-Nog transgenic mice.  To suppress BMP signaling in the 
stomach, we constructed K19-Nog mice that expressed Nog encoding noggin in 
gastric epithelial cells (Fig. 1A).  Noggin is a polypeptide that inhibits BMP signaling 
by binding BMP ligands (4).  We confirmed increased levels of Nog mRNA in 
K19-Nog mouse stomach compared with that in the wild-type by real-time RT-PCR 
(Fig. 1B).  BMP type I receptor phosphorylates Smad1,5,8 upon complex formation 
with BMP ligand and type II receptor (3).  We found phosphorylated Smad1,5,8 by 
immunohistochemistry in the nuclei of differentiated epithelial cells both at the 
surface and bottom of the gastric gland (Fig. 1C), which is consistent with a previous 
report (11).  Notably, in the K19-Nog mice, the immunostaining signals of 
phosphorylated Smad1,5,8 decreased significantly in the upper gastric gland where 
the K19 promoter is transcriptionally active (Fig. 1C, D).  These results indicate that 
exogenous Nog expression inhibits BMP signaling in the stomach.   
Construction of compound mutant mice.  We previously constructed 
K19-C2mE transgenic mice expressing both Ptgs2 and Ptges encoding COX-2 and 
mPGES-1, respectively, in gastric mucosa (Fig. 1A, D).  Expression of COX-2 and 
mPGES-1 leads to increase of PGE2 level in K19-C2mE mouse stomach (16).  To 
investigate the effect of the PGE2 pathway in BMP-suppressed gastric mucosa, we 
crossed K19-Nog and K19-C2mE mice to generate K19-Nog/C2mE compound mice.  
We confirmed expression of Ptgs2 by real-time RT-PCR in the stomach of 
K19-C2mE and K19-Nog/C2mE mice, but not in wild-type and K19-Nog mice (Fig. 
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1B).  We also used K19-Wnt1/C2mE mice for this study that develop gastric 
adenocarcinoma caused by simultaneous activation of the Wnt and PGE2 pathways 
(17).  Genotypes of respective transgenic strains were confirmed by genomic PCR 
(Supplementary Fig. 1). 
Gastric tumor development in K19-Nog/C2mE mice.  K19-Nog mice did not 
develop tumorous lesions in the stomach, and the histology of gastric glands was 
normal (Supplementary Fig. 2, and Fig. 2A).  In contrast, K19-C2mE mice developed 
inflammation-associated hyperplasia, and K19-Wnt1 mice developed dysplastic 
preneoplastic lesions, which were consistent with previous reports (16, 17).  
Importantly, K19-Nog/C2mE mice develop large tumors in the glandular stomach 
(Supplementary Fig. 2, and Fig. 2A).  These results suggest that suppression of 
BMP signaling is insufficient for gastric tumorigenesis, but that cooperation of BMP 
inhibition and PGE2 induction cause gastric tumor development.  Such an effect of 
PGE2 on tumorigenesis was similar to that found in K19-Wnt1/C2mE mice.  
Activation of Wnt/β-catenin alone leads to development of small preneoplastic 
lesions, whereas simultaneous activation of the Wnt/β-catenin and PGE2 pathways 
cause gastric adenocarcinoma (17, and Fig. 2A).  Therefore, PGE2 plays an 
important role in tumorigenesis regardless of the types of genetic alterations.   
JP-type hamartoma in K19-Nog/C2mE mouse stomach.  Histologically, 
gastric tumors in K19-Nog/C2mE mice displayed irregular branching of epithelial cell 
layers, combined with dilated cysts that were filled with mucin (Fig. 2B and C).  Such 
histological characteristics were different from dysplastic tumors of the 
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K19-Wnt1/C2mE mice (17, and Fig 2B).  We also found abundant α-smooth muscle 
actin-positive myofibroblasts in stroma.  Moreover, we detected infiltration of 
F4/80-positive macrophages and the accumulation of lymphocytes in the 
K19-Nog/C2mE tumors (Fig. 2C).  These histological characteristics are typical of 
the hamartoma of JP patients (9, 10, 18), indicating that suppression of BMP 
signaling associated with PGE2 induction causes development of JP-type gastric 
hamartoma.  However, tumor incidence in K19-Nog/C2mE mice was 23%, whereas 
that in K19-Wnt1/C2mE mice was 100% (Supplementary Table).  Notably, 
expression of inflammatory cytokine TNF-α increased in K19-Nog/C2mE 
hamartomas as well as in K19-C2mE hyperplasia (Supplementary Fig. S3).  
However, TNF-α was not induced in non-tumor stomach of K19-Nog/C2mE mice, 
while transgenic expression of Ptgs2 stayed at the same level as that in tumor 
tissues.  These results suggest that inflammatory response is also important for 
hamartoma development together with BMP suppression and PGE2 induction.  
Suppression of gastric hamartoma by COX-2 inhibition.  To investigate 
whether the PGE2 pathway is required for gastric hamartoma development, we 
treated K19-Nog/C2mE mice with a COX-2 selective inhibitor, celecoxib, at 100 
mg/kg/day for 3 weeks.  We examined gastric tumor size by X-ray CT scanning, and 
found that the tumor volume of K19-Nog/C2mE mice decreased significantly by 
celecoxib treatment (Fig. 3A).  The mean relative tumor size on CT images reduced 
to 58% after celecoxib treatment (Fig 3B).  Histologically, cystic structures were no 
longer found, and necrotic area was detected in the celecoxib-treated 
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K19-Nog/C2mE tumors (Fig. 3C).  The PGE2 pathway is important for angiogenesis 
of gastrointestinal tumorigenesis (15, 19).  Consistently, the number of capillary 
vessels decreased significantly in celecoxib-treated K19-Nog/C2mE tumors (Fig. 
3D).  Accordingly, it is possible that angiogenesis is one of the important functions of 
PGE2 for hamartoma development. 
Wnt-independent development of gastric hamartoma.  In the intestinal crypt, 
inhibition of BMP signaling results in activation of the Wnt/β-catenin pathway (7).  We 
thus examined activation of Wnt signaling in K19-Nog/C2mE gastric tumors.  The 
level of the active β-catenin did not increase in K19-Nog/C2mE hamartomas, while it 
elevated markedly in K19-Wnt1/C2mE tumors (Fig. 4A).  Consistently, expression of 
Wnt target genes in K19-Nog/C2mE tumors stayed at the same level as that in 
wild-type mouse stomach, while these genes were upregulated in K19-Wnt1/C2mE 
tumors (Fig. 4B).  We confirmed that inflammatory cytokines and chemokines were 
induced in both K19-Nog/C2mE and K19-Wnt1/C2mE tumors.  Accordingly, 
activation of Wnt signaling is not involved in hamartoma development in 
BMP-suppressed gastric mucosa, although PGE2 signaling or PGE2-dependent 
inflammation may be required for both adenocarcinoma and hamartoma.   
We next examined expression of PGE2 receptors, EP1 to EP4 in tumor tissues.  
Notably, the expression of Ptger1, Ptger2, and Ptger3 encoding EP1, EP2, and EP3, 
respectively, decreased significantly in tumors of K19-Nog/C2mE and 
K19-Wnt1/C2mE mice (Fig. 4C).  In contrast, expression of Ptger4 encoding EP4 
increased dramatically in both K19-Nog/C2mE hamartomas and K19-Wnt1/C2mE 
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adenocarcinomas.  These results suggest that PGE2 signaling through EP4 is 
important for development of both gastric hamartoma and adenocarcinoma.  Namely, 
it is possible that the type of genetic alterations determines the histological 
phenotype of tumors, hamartoma or adenocarcinoma, and that the induced PGE2 
pathway promotes tumor growth through EP4 receptor regardless of histological 
types (Supplementary Fig. S4).   
In human stomach, expression of COX-2 is induced in Helicobacter 
pylori-associated gastric lesions (20).  Accordingly, it is conceivable that H. pylori 
infection contributes to the development of gastric hamartoma through induction of 
the PGE2 pathway.  Therefore, inhibition of the PGE2 pathway as well as eradication 
of H. pylori may be an effective preventive strategy not only for gastric cancer but 
also for gastric hamartoma. 
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Figure 1.  Generation of transgenic mice.  A, transgenic vectors.  B, relative mRNA 
levels (Mean ± S.D.) of Nog and Ptgs2 in the gastric mucosa of K19-Nog (Nog), 
K19-C2mE (C2mE), and K19-Nog/C2mE (Nog/C2mE) mice to the wild-type (WT).  
Asterisks, p < 0.05.  C, immunohistochemistry of phosphorylated Smad1,5,8 in 
gastric mucosa of wild-type and K19-Nog mice.  Arrowheads and arrows indicate 
positive nuclear staining in surface and gland bottom, respectively.  Asterisks 
indicate decreased immunostaining signal in K19-Nog mouse.  D, 
immunohistochemistry of COX-2 in wild-type and K19-C2mE mouse stomach.  
Arrows indicate transgenic expression of COX-2 in K19-C2mE gastric mucosa 
where K19 promoter is transcriptionally active.  Bars, 100 μm. 
 
Figure 2.  Gastric tumors developed in K19-Nog/C2mE mice.  A, macroscopic 
photographs and H&E of K19-Nog, K19-C2mE, and K19-Wnt1 mouse stomach (top).  
Arrowheads and asterisks in K19-C2mE indicate hyperplasia, and arrows indicate 
inflammatory infiltration.  Arrowhead and inset in K19-Wnt1 indicate preneoplastic 
lesion.  Gastric tumors in K19-Nog/C2mE and K19-Wnt1/C2mE mice are shown 
(arrows, bottom).  Bars, 10 mm.  B. Histology of gastric tumors of K19-Nog/C2mE 
and K19-Wnt1/C2mE (H&E).  Bars, 200 μm.  C, PAS-Alcian blue, immunostaining for 
αSMA, F4/80, and H&E of K19-Nog/C2mE hamartomas (from left to right).  Asterisks 
indicate dilated cysts.  Arrows indicate lymphocyte accumulation.  Bars, 100 μm. 
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Figure 3.  Suppression of hamartoma development by COX-2 inhibition.  A, X-ray 
CT images of gastric tumors of the same K19-Nog/C2mE mouse (yellow dashed 
lines) at 0 and 3 weeks of celecoxib treatment.  B, relative tumor size at each time 
point of celecoxib treatment to the level at 0 week (Mean ± S.D.).  C, representative 
photograph and H&E of celecoxib-treated K19-Nog/C2mE tumors.  Arrow and 
asterisk indicate necrotic area.  D, immunostaining for vWF.  Arrows indicate 
vWF-positive capillary vessels.  Microvessel densities (MVD) are shown (Mean ± 
S.D.).  Asterisks, p < 0.05.   
 
Figure 4.  Wnt activity and EP expression in gastric hamartomas.  A, Western 
blotting for active β-catenin in the stomach of each genotype.  B, relative expression 
levels determined by microarray analyses of Wnt target genes and 
cytokines/chemokines in K19-Wnt1/C2mE and K19-Nog/C2mE tumors to the 
wild-type level.  C, relative expression levels of PGE2 receptors, Ptger1, Ptger2, 
Ptger3, and Ptger4 in K19-C2mE hyperplasia, K19-Nog/C2mE hamartoma, and 
K19-Wnt1/C2mE adenocarcinoma (Mean ± S.D.).  Asterisks, p < 0.05.   
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